Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION The working file is CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. The population in CMC comparability package for a site change is the one an FAERS cluster in a demographic the trials under-enrolled named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in CMC comparability package for a site change is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; Pause the pathway is the honest Pharma & Life Sciences call. 3. A mid-size sponsor after a complete response letter already contained an FAERS cluster in a demographic the trials under-enrolled before CMC comparability package for a site change arrived; no new CMC and Development Pathways path. 4. Provenance on CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 3. Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.